Background: The aim of this study was to assess the efficacy of dienogest treatment in improving quality of life in women with endometriosis. Methods: This was a prospective observational multicenter study at the universities of Siena, Milano, Cagliari, Perugia, Busto Arstizio, Pisa, Padova, Palermo, Foggia, Roma, Pescara and Catanzaro, including 142 patients with a diagnosis of endometriosis who received dienogest 2 mg once daily, for up to 90 days. Each patient underwent an evaluation of pelvic pain measured by visual analogue scale (VAS) from 0 to 10 points, and of quality of life measured by a mental and physical index before and after treatment. Results: The mean ± SD of VAS was 8.2 ± 1.6 in women with endometriosis, and this progressively and signifi- cantly decreased to 5.9 ± 2.6 at the end of the study. Mental index score values increased from 39.0 ± 9.8 to 46.0 ± 9.1 (p<0.001); likewise, the physical index increased from 39.6 ± 9.6 to 47.7 ± 8.5 (p<0.001). During the treatment period, the most frequent adverse events (AEs) were headache (30.8%), followed by bleeding (29.4%), depres- sion (26.6%), breast tenderness (23.8%) and acne (2.0%), but these were transitory, and none led to withdrawal from the study. Conclusions: The present prospective study showed that dienogest is an effective and well-tolerated treatment improving the quality of life in endometriotic women.

Dienogest treatment improves quality of life in women with endometriosis / S. Luisi, F. Parazzini, S. Angioni, S. Arena, P. Berretta, M. Candiani, V. Cela, L. Fedele, P. Litta, A. Maiorana, L. Nappi, M.G. Porpora, M. Rosati, F. Zullo, C. Tosti, F. Petraglia. - In: JOURNAL OF ENDOMETRIOSIS AND PELVIC PAIN DISORDERS. - ISSN 2284-0265. - 7:4(2015), pp. 124-128. [10.5301/je.5000232]

Dienogest treatment improves quality of life in women with endometriosis

F. Parazzini;M. Candiani;L. Fedele;
2015

Abstract

Background: The aim of this study was to assess the efficacy of dienogest treatment in improving quality of life in women with endometriosis. Methods: This was a prospective observational multicenter study at the universities of Siena, Milano, Cagliari, Perugia, Busto Arstizio, Pisa, Padova, Palermo, Foggia, Roma, Pescara and Catanzaro, including 142 patients with a diagnosis of endometriosis who received dienogest 2 mg once daily, for up to 90 days. Each patient underwent an evaluation of pelvic pain measured by visual analogue scale (VAS) from 0 to 10 points, and of quality of life measured by a mental and physical index before and after treatment. Results: The mean ± SD of VAS was 8.2 ± 1.6 in women with endometriosis, and this progressively and signifi- cantly decreased to 5.9 ± 2.6 at the end of the study. Mental index score values increased from 39.0 ± 9.8 to 46.0 ± 9.1 (p<0.001); likewise, the physical index increased from 39.6 ± 9.6 to 47.7 ± 8.5 (p<0.001). During the treatment period, the most frequent adverse events (AEs) were headache (30.8%), followed by bleeding (29.4%), depres- sion (26.6%), breast tenderness (23.8%) and acne (2.0%), but these were transitory, and none led to withdrawal from the study. Conclusions: The present prospective study showed that dienogest is an effective and well-tolerated treatment improving the quality of life in endometriotic women.
Dienogest; Endometriosis; Pelvic pain; Quality of life; Stress
Settore MED/40 - Ginecologia e Ostetricia
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/445748
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact